On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA less than the lower limit of quantification (LLOQ) 24 weeks off all ...

Arbutus Biopharma (ABUS) announced new data from its IM-PROVE I Phase 2a clinical trial showing that six doses of imdusiran, the ...

Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Cite this: The Antifibrotic Effect of Interferon Alfa in the Treatment of Chronic Hepatitis C: An Unanticipated but Important End Point - Medscape - Jun 13, 2000. Dr. Dufour is Assistant Professor ...

Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...

What Casanova’s team learned by studying her cells could benefit other patients, as well. “Had we known the patient had IRF7 deficiency when she was admitted, perhaps she would have benefited from ...

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...